Go Deep
CORONA Remedies Limited
CORONA Remedies Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 16,795 | 63.8 | 16.95 | 0.22 | 2,070.10 |
| Sep 2026 | 16,739 | 63.7 | 17.02 | 0.22 | 2,078.40 |
| Oct 2026 | 16,004 | 64.5 | 17.14 | 0.22 | 2,093.40 |
| Oct 2026 | 16,435 | 62.5 | 16.62 | 0.22 | 2,029.40 |
| Oct 2026 | 16,435 | 62.5 | 16.62 | 0.22 | 2,029.40 |
| Oct 2026 | 16,435 | 62.5 | 16.62 | 0.22 | 2,029.40 |
| Oct 2026 | 16,321 | 62.5 | 16.62 | 0.22 | 2,029.40 |
| Oct 2026 | 16,321 | 62.3 | 16.62 | 0.22 | 2,029.40 |
| Oct 2026 | 16,424 | 62.5 | 16.66 | 0.22 | 2,034.20 |
| Oct 2026 | 16,398 | 62.6 | 16.69 | 0.22 | 2,038.30 |
| Oct 2026 | 16,380 | 62.7 | 16.71 | 0.22 | 2,041.10 |
| Oct 2026 | 16,547 | 61.3 | 16.32 | 0.22 | 1,993.50 |
| Oct 2026 | 16,355 | 62.2 | 16.57 | 0.22 | 2,024.00 |
| Oct 2026 | 16,355 | 62.2 | 16.57 | 0.22 | 2,024.00 |
| Oct 2026 | 15,665 | 62.2 | 16.57 | 0.22 | 2,024.00 |
| Oct 2026 | 15,665 | 62.2 | 16.57 | 0.22 | 2,024.00 |
| Oct 2026 | 15,830 | 61.6 | 16.50 | 0.22 | 2,015.30 |
| Oct 2026 | 15,761 | 62.3 | 16.59 | 0.22 | 2,026.20 |
| Oct 2026 | 15,551 | 63.3 | 16.87 | 0.22 | 2,059.60 |
| Oct 2026 | 15,644 | 62.8 | 16.75 | 0.22 | 2,044.80 |
| Oct 2026 | 15,902 | 61.6 | 16.41 | 0.22 | 2,003.90 |
| Oct 2026 | 15,902 | 61.6 | 16.41 | 0.22 | 2,003.90 |
| Oct 2026 | 15,902 | 61.6 | 16.41 | 0.22 | 2,003.90 |
| Oct 2026 | 15,864 | 61.8 | 16.46 | 0.22 | 2,010.00 |
| Oct 2026 | 15,864 | 61.8 | 16.46 | 0.22 | 2,010.00 |
| Oct 2026 | 15,795 | 62.1 | 16.55 | 0.22 | 2,020.90 |
| Oct 2026 | 15,650 | 62.8 | 16.74 | 0.22 | 2,043.80 |
CORONA Remedies Limited Quarterly Results
| Line Item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 3,530,900,000.0 | 3,424,200,000.0 | 3,611,300,000.0 | 3,465,400,000.0 |
| Net Profit | 453,300,000.0 | 412,700,000.0 | 523,200,000.0 | 462,000,000.0 |
| EPS | 7.4 | 6.8 | 8.6 | 7.6 |
CORONA Remedies Limited Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 14,014,800,000.0 | 11,955,100,000.0 | 10,136,820,000.0 | 8,835,280,000.0 |
| Net Profit | 1,851,200,000.0 | 1,494,300,000.0 | 905,030,000.0 | 849,290,000.0 |
| EPS | 30.3 | 24.4 | 14.8 | 13.9 |
CORONA Remedies Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Total Assets | 12,051,400,000.0 | 9,298,600,000.0 | 8,305,760,000.0 | 5,950,240,000.0 |
| Total Liabilities | 4,582,800,000.0 | 3,235,200,000.0 | 3,501,690,000.0 | 1,865,040,000.0 |
| Total Equity | 7,468,600,000.0 | 6,063,400,000.0 | 4,804,070,000.0 | 4,085,200,000.0 |
Owes vs Owns
CORONA Remedies Limited owed ₹0.38 for every ₹1 it owned in Mar 2026, up from ₹0.31 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.38× | 0.35× | 0.42× | 0.31× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
CORONA Remedies Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Receivables 12.1%Inventory 10.4%Fixed assets (tangible) 36.3%Intangible assets 21.8%Long-term investments 2.2%Other assets 17.1%
How it's funded — Mar 2026
Short-term debt 11.9%Payables 12.2%Other liabilities 14.0%Shareholders' equity 62.0%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 1.8 | 3.2 | 3.2 | 20.5 |
| Receivables | 145.6 | 118.3 | 99.9 | 87.0 |
| Inventory | 125.0 | 129.5 | 98.3 | 105.4 |
| Fixed assets (tangible) | 437.8 | 392.6 | 319.0 | 257.4 |
| Intangible assets | 262.8 | 171.2 | 192.7 | 0.5 |
| Long-term investments | 26.1 | 25.9 | 25.5 | 25.5 |
| Other assets | 206.0 | 89.3 | 92.0 | 98.8 |
| Liabilities & equity | ||||
| Short-term debt | 142.9 | 46.7 | 67.1 | 2.3 |
| Long-term debt | 0.0 | 16.0 | 67.0 | 0.0 |
| Payables | 147.1 | 143.5 | 114.3 | 94.4 |
| Other liabilities | 168.3 | 117.3 | 101.7 | 89.8 |
| Shareholders' equity | 746.9 | 606.3 | 480.4 | 408.5 |
| Net tangible assets | 484.0 | 435.2 | 287.7 | 408.0 |
CORONA Remedies Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Operating Activities | 2,294,800,000.0 | 1,904,900,000.0 | 1,567,580,000.0 | 1,027,000,000.0 |
| Investing Activities | -2,561,500,000.0 | -838,600,000.0 | -2,666,430,000.0 | -502,450,000.0 |
| Financing Activities | 252,800,000.0 | -1,065,700,000.0 | 985,450,000.0 | -447,470,000.0 |